TRVI Stock Discussion
Trevi Therapeutics, Inc. Description
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Organic Compounds Chemical Compounds Opioids Analgesics Idiopathic Pulmonary Fibrosis Ethers Pulmonary Fibrosis Nervous System Morphinans Physiology Cough Phenols Parkinson’s Disease Opioid Receptors Pruritus Dyskinesia Peripheral Nervous System Prurigo Prurigo Nodularis
Recent Comments
- TraderMike on BOOT
- Dr_Duru on BOOT
- TraderMike on Stochastic Reached Oversold
- SuccessfulGrasshopper897 on Stochastic Reached Oversold
- Cos3 on Adding float as advanced filter criteria?
From the Blog
Popular Now
Featured Articles